Tali Aben - Allovir Non-Executive Independent Director

ALVR
 Stock
  

USD 8.76  0.25  2.77%   

  Director
Ms. Tali Aben is NonExecutive Independent Director of Alvarion Ltd. since November 2011. Since 2008 she was advising international investors on opportunities within the Israeli Hightech sector. Ms. Aben also serves as an External Director of Attunity Ltd. and Vizrt Ltd. as well as several privatelyheld companies and nonprofit organizations. Previously Ms. Aben was a General Partner with Gemini Israel Funds a VC firm which she joined in 1994. At Gemini she funded and supported many companies including Verisity Jacada Abirnet Business Layers Servicesoft nLayers and others. Her focus was primarily on software companies expanding in 2007 to include cleantech companies
Age: 46  Director Since 2011  MBA    
617 433 2605  https://www.allovir.com
Aben holds a B.Sc. in Math and Computer Science and an MBA, both from Tel Aviv University.

Allovir Management Efficiency

Allovir has return on total asset (ROA) of (39.1) % which means that it has lost $39.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (70.84) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 23.13 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 10.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Allovir until it has trouble settling it off, either with new capital or with free cash flow. So, Allovir's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allovir sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allovir to invest in growth at high rates of return. When we think about Allovir's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Giacomo FerragamoSALVATORE FERRAGAMO
2018
David TylerBurberry
N/A
Martha WikstromCie Financiere Rich
2013
Thomas LindemannCie Financiere Rich
N/A
Vai ChungLuk Fook Holdings
2015
Niccolo MonteleraBirks Group
2010
Hau WongLuk Fook Holdings
2011
Nicolas BazireChristian Dior SE
2017
Po YeungLuk Fook Holdings
N/A
Duke WellingtonCie Financiere Rich
2000
Marzio SaaSALVATORE FERRAGAMO
2011
Diego GiulianoSALVATORE FERRAGAMO
N/A
Alan QuashaCie Financiere Rich
2000
HansPeter BichelmeierCie Financiere Rich
2012
Elizabeth EveillardBirks Group
2005
Alessandro CorsiSALVATORE FERRAGAMO
2011
Anton RupertCie Financiere Rich
2017
Chiara AmbrosettiSALVATORE FERRAGAMO
N/A
Keyu JinCie Financiere Rich
2017
Lord DouroCie Financiere Rich
2000
Helene DesmaraisChristian Dior SE
2012
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 110 people.

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Doron Inbar, Non-Executive Independent Director
Raphael Amit, External Director
Zeev Farkash, Executive Vice President - Sales
Assaf Katan, Acting President and CEO
Moshe Fourier, Executive Vice President-R&D
Tali Aben, Non-Executive Independent Director
Mati Wax, CTO
Avi Stern, CFO
Amnon Yacoby, Independent Chairman of the Board
Nir Golan, Executive Vice President
Ziv Eizenberg, Executive Vice President-Human Resources
Leor Porat, Executive Vice President General Counsel

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allovir in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allovir's short interest history, or implied volatility extrapolated from Allovir options trading.

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving against Allovir

-0.57MRNAModerna Potential GrowthPairCorr
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.